Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;10(5):425-428.
doi: 10.1159/000538405. Epub 2024 May 3.

Corticosteroid Atrophy Plaque on the Scalp Treated with 5-Fluourouracil and Bleomycin Infusion in the MMP Technique

Luciana Gasques  1 , Fernanda Freitas de Brito  2 , Raissa Zobiole  1 , Letícia Bortolini  3 , Vanessa Catalá Casteli Assumpção  4 , Caio Leal Carvalho  4
Affiliations

Corticosteroid Atrophy Plaque on the Scalp Treated with 5-Fluourouracil and Bleomycin Infusion in the MMP Technique

Luciana Gasques et al. Skin Appendage Disord. 2024 Oct.

Abstract

Alopecia areata (AA) is a disease with a great impact on quality of life of patients. Among several treatment modalities, intralesional injectable corticosteroid therapy is the first option, with corticosteroid-induced cutaneous atrophy as a common adverse event. We describe a case of plaque AA in the frontal region of the scalp that evolved with cutaneous atrophy induced by the application of intralesional corticosteroids but presented complete and sustained repilation after being treated with 5-Fluorouracil and Bleomycin using the technique of MMP (Microinfusion of Medicines into the Skin).

Keywords: Alopecia; Alopecia areata; Atrophy; Corticosteroids; Hair.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1.
Fig. 1.
Plaque of erythematous-atrophic alopecia with a shiny and hardened background in the frontal region of the scalp measuring approximately 3 × 8 cm.
Fig. 2.
Fig. 2.
Trichoscopy showed telangiectasia, dystrophic hair, black dots, white dots, yellow dots, and exclamation mark hair.
Fig. 3.
Fig. 3.
Non-scarring alopecia without inflammatory activity with a proportional numerical increase in miniaturized hairs and several follicles in the terminal phase of catagen.
Fig. 4.
Fig. 4.
Complete repilation of the treated area after treatment with 5-FU and Bleomycin in the MMP technique.
Fig. 5.
Fig. 5.
Complete repilation maintained after more than 5 years of follow-up with post-treatment with 5-FU and Bleomycin in the MMP technique.
See this image and copyright information in PMC

References

    1. Juárez-Rendón KJ, Rivera Sánchez G, ReyesLópez MÁ, García-Ortiz JE, Bocanegra-García V, Guardiola-Avila I, et al. Alopecia Areata. Current situation and perspectives. Arch Argent Pediatr. 2017;115(6):e404–11. - PubMed
    1. Ramos PM, Anzai A, Duque-Estrada B, Melo DF, Sternberg F, Santos LDN, et al. Consensus on the treatment of alopecia areata – Brazilian Society of Dermatology. Bras Dermatol. 2020;95(Suppl 1):39–52. - PMC - PubMed
    1. Chu TW, Aljasser M, Alharbi A, Abahussein O, McElwee K, Shapiro J. Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: an intrasubject pilot study. J Am Acad Dermatol. 2015;73(2):338–40. - PubMed
    1. Shumaker P, Rao J, Goldman M. Treatment of local, persistent cutaneous atrophy following corticosteroid injection with normal saline infiltration. Dermatol Surg. 2005;31(10):1340–3. - PubMed
    1. Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by rochester epidemiology project, 1990-2009. J Invest Dermatol. 2014;134(4):1141–2. - PMC - PubMed

LinkOut - more resources